Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 3b SEQUENCE Trial

被引：0

作者：

Peyrin-Biroulet, L. ^{[1
]}

Bossuyt, P. ^{[2
]}

Regueiro, M. ^{[3
]}

Schreiber, S. ^{[4
]}

Gecse, K. ^{[5
]}

Irving, P. ^{[6
]}

D'Haens, G. ^{[5
]}

Cao, Q. ^{[7
]}

Neimark, E. ^{[8
]}

Huang, X. ^{[9
]}

Anschutz, T. ^{[8
]}

Kligys, K. ^{[10
]}

O'Brien, D. ^{[10
]}

Panaccione, R. ^{[11
]}

机构：

[1] Univ Hosp Nancy Brabois, Dept Gastroenterol, Vandoeuvre Les Nancy, France

[2] Imelda Gen Hosp, Imelda GI Clin Res Ctr, Dept Gastroenterol, Bonheiden, Belgium

[3] Cleveland Clin, Dept Gastroenterol Hepatol & Nutr, Cleveland, OH 44106 USA

[4] Univ Kiel, Dept Med 1, Univ Hosp Schleswig Holstein, Kiel, Germany

[5] Amsterdam Univ Med Ctr, Dept Gastroenterol & Hepatol, Locat AMC, Amsterdam, Netherlands

[6] Guys & St Thomas NHS Fdn Trust, Gastroenterol Guys & St Thomas Hosp, London, England

[7] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Gastroenterol, Coll Med, Hangzhou, Peoples R China

[8] AbbVie, Clin Dev, N Chicago, IL 60064 USA

[9] AbbVie, Stat, N Chicago, IL 60064 USA

[10] AbbVie, Med Affairs, N Chicago, IL 60064 USA

[11] Univ Calgary, Div Gastroenterol & Hepatol, Inflammatory Bowel Dis Unit, Calgary, AB, Canada

来源：

JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP10

引用

页码：I90 / I91

页数：2

共 50 条

[41] Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
Eyerich, Kilian
Gottlieb, Alice B.
Piaserico, Stefano
Beissert, Stefan
Gooderham, Melinda
Kirby, Brian
Tilt, Nicola
Madden, Cynthia
Wiegratz, Susanne
de Cuyper, Dirk
Elewski, Boni
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB22 - AB22
[42] EFFICACY AND SAFETY OF OPEN-LABEL MAINTENANCE THERAPY WITH SUBCUTANEOUS RISANKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
Feagan, Brian G.
Panes, Julian
Ferrante, Marc
Kaser, Arthur
D'Haens, Geert R.
Sandborn, William J.
Louis, Edouard
Neurath, Markus
Franchimont, Denis
Dewit, Olivier
Seidler, Ursula
Kim, Kyung-Jo
Selinger, Christian
Padula, Steven J.
Herichova, Ivona
Robinson, Anne M.
Wallace, Kori
Zhao, Jun
Soaita, Adina
Visvanathan, Sudha
Hall, David
Bocher, Wulf O.
[J]. GASTROENTEROLOGY, 2017, 152 (05) : S1310 - S1310
[43] CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL
Peyrin-Biroulet, Laurent
Vermeire, Severine
D'Haens, Geert R.
Panes, Julian
Dignass, Axel
Magro, Fernando
Nazar, Maciej
Le Bars, Manuela
Lahaye, Marjolein
Ni, Lioudmila
Bravata, Ivana
Lavie, Frederic
Daperno, Marco
Lukas, Milan
Armuzzi, Alessandro
Lowenberg, Mark
Gaya, Daniel R.
Danese, Silvio
[J]. GASTROENTEROLOGY, 2022, 162 (07) : S801 - S801
[44] Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
Danese, Silvio
Vermeire, Severine
D'Haens, Geert
Panes, Julian
Dignass, Axel
Magro, Fernando
Nazar, Maciej
Le Bars, Manuela
Lahaye, Marjolein
Ni, Lioudmila
Bravata, Ivana
Lavie, Frederic
Daperno, Marco
Lukas, Milan
Armuzzi, Alessandro
Lowenberg, Mark
Gaya, Daniel R.
Peyrin-Biroulet, Laurent
[J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (04): : 294 - 306
[45] Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease
Moens, A.
Verstockt, B.
Alsoud, D.
Sabino, J.
Ferrante, M.
Vermeire, S.
[J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I423 - I424
[46] Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease
Moens, A.
Verstockt, B.
Alsoud, D.
Sabino, J.
Ferrante, M.
Vermeire, S.
[J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I423 - I424
[47] Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial
Colombel, Jean-Frederic
Sandborn, William J.
Rutgeerts, Paul
Kamm, Michael A.
Yu, Andrew P.
Wu, Eric Q.
Pollack, Paul F.
Lomax, Kathleen G.
Chao, Jingdong
Mulani, Parvez M.
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (05): : 1170 - 1179
[48] Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST
Peyrin-Biroulet, Laurent
Vermeire, Severine
D'Haens, Geert
Panes, Julian
Dignass, Axel
Magro, Fernando
Nazar, Maciej
Le Bars, Manuela
Lahaye, Marjolein
Ni, Lioudmila
Bravata, Ivana
Lavie, Frederic
Daperno, Marco
Lukas, Milan
Armuzzi, Alessandro
Loewenberg, Mark
Gaya, Daniel R.
Danese, Silvio
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 175 - 185
[49] Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein analysis: results from the UNITI-1 and UNITI-2 Phase 3 induction studies
Li, K.
Hayden, K.
Wadman, E.
Bhagat, S.
Emrich, S.
Friedman, J. R.
Gasink, C.
Brodmerkel, C.
[J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S26 - S27
[50] USTEKINUMAB IS EFFECTIVE FOR INDUCING CLINICAL, ENDOSCOPIC, AND RADIOGRAPHIC RESPONSE AND REMISSION IN REFRACTORY MODERATE-TO-SEVERE CROHN'S DISEASE: A MULTICENTRE COHORT STUDY
Ma, Christopher
Fedorak, Richard N.
Kaplan, Gilaad
Dieleman, Levinus A.
Devlin, Shane M.
Stern, Nathan
Kroeker, Karen I.
Seow, Cynthia H.
Leung, Yvette
Novak, Kerri L.
Halloran, Brendan P.
Huang, Vivian
Wong, Karen
Ghosh, Subrata
Panaccione, Remo
[J]. GASTROENTEROLOGY, 2017, 152 (05) : S410 - S411

← 1 2 3 4 5 →